ASX-listed digital health company to harness AI in Alzheimer’s and dementia diagnosis

Digital Health & Innovation: An ASX-listed digital healthcare company, specializing in AI-driven diagnostics for neurological disorders, is participating in a clinical study aimed at enhancing the early and accurate diagnosis of dementia, specifically frontotemporal dementia (FTD) and Alzheimer’s Disease (AD), through innovative AI-powered diagnostic tools.

Partnering with Erasmus University Medical Centre (Erasmus MC) in Rotterdam, BlinkLab will leverage its cutting-edge AI technology within the newly established Digital Dementia Lab. This lab serves as a home-based testing environment designed to develop and assess digital biomarkers, focusing on clinically relevant behaviours to improve early diagnosis of Alzheimer’s and dementia.

The partnership grants BlinkLab an exclusive option to license any new intellectual property arising from the study.

Henk-Jan Boele, CEO of BlinkLab, stated “This work will be an important driver for the transformation of mental healthcare from the current one-size-fits-all approach to a data-driven, personalised, and affordable system. I am looking forward to working with Dr Jackie Poos and we are confident that our collaboration will offer new possibilities for the advancement of dementia diagnosis and care.”

Brian Leedman, Chairman of BlinkLab, echoed the sentiment, emphasizing the strategic significance of partnering with a top-tier research institution like Erasmus MC. He stated, “This collaboration validates our innovative solutions and underscores the potential of our technology to revolutionise the diagnosis and management of dementia, complementing our ongoing work in autism and ADHD.”

In recent years, BlinkLab has made significant strides in developing a smartphone-based diagnostic platform for various neuropsychiatric conditions, including autism, ADHD, and schizophrenia.

Their most advanced product is an autism diagnostic test leveraging smartphones, AI, and machine learning, specifically designed for children as young as 18 months old. This advancement is crucial, considering traditional diagnoses typically occur around five years of age, often missing the critical early intervention window.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.